Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05201703 · ClinicalTrials.gov registry record · Phase 4
Fycompa in Catamenial Epilepsy
A Phase 4 study, sponsored by University of Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT05201703: Clinical Trial Phase 4 study, sponsored by University of Florida.
NCT05201703 is a Phase 4 study that was terminated before completion, run by University of Florida. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05201703, a Phase 4 study, was terminated before completion, sponsored by University of Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This mechanism of action would allow a novel use of perampanel as an effective treatment of C1 catamenial epilepsy.
Primary Outcome
To measure the 50% responder rate will be analyzed using Chi square analysis.
Interventions
- DRUG Fycompa
- DRUG Fycompa with a boost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2023-12-15 |
| Phase | Phase 4 |
Why NCT05201703 stopped before completion
NCT05201703 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Fycompa is the first listed.
NCT05201703 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05201703 about?
NCT05201703 is a clinical study titled "Fycompa in Catamenial Epilepsy". The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel (Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated excitotoxicity. This m...
What is the current status of trial NCT05201703?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2022-03-09. Estimated completion is 2023-12-15.
What interventions are being tested in trial NCT05201703?
The interventions under investigation include: Fycompa (DRUG), Fycompa with a boost (DRUG).
Who is sponsoring clinical trial NCT05201703?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05201703's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI